IDXX — IDEXX Laboratories, Inc.

IDEXX Laboratories Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q4 Revenue: Increased by 14% (12% organic growth), driven by a 10% organic growth in CAG Diagnostics recurring revenues.
• EPS: Reported at $3.08, up 17% year-over-year on a comparable basis; full-year EPS reached $13.08, a 14% increase.
• Operating Margins: Q4 operating margins improved to 31.6%, up 90 basis points year-over-year; full-year margins also at 31.6%.
• Free Cash Flow: For 2025, free cash flow was $1.1 billion, representing 100% of net income.
• Instrument Placements: Achieved record placements with over 6,500 premium instruments in Q4, contributing to a 12% expansion of the global premium instrument installed base.

2. Strategic Updates and Business Highlights:

• IDEXX launched multiple innovations, including the InVue DX platform and expanded capabilities for the CancerDx panel, enhancing diagnostic offerings.
• The company successfully expanded its commercial presence in key international markets, including Germany, the UK, and Australia.
• IDEXX reported strong customer retention rates in the high nineties for its CAG Diagnostics business, indicating robust customer loyalty.
• The software segment, particularly the Velo platform, showed strong growth, with a 40% increase in users, contributing to improved clinic engagement and diagnostic utilization.

3. Forward Guidance and Outlook:

• For 2026, IDEXX anticipates revenue between $4.632 billion and $4.72 billion, representing a 7.6% to 9.6% increase on a reported basis.
• CAG Diagnostics recurring revenue is expected to grow 8% to 10% organically.
• Operating margins are projected to improve to between 32% and 32.5% for the full year.
• Q1 2026 guidance indicates reported revenue growth of 11.5% to 13.5%, with organic growth of 9% to 11%.

4. Bad News, Challenges, or Points of Concern:

• There are ongoing pressures on clinical visits, with a decline of approximately 1.7% in Q4 and 1.9% for the full year, particularly affecting wellness visits.
• IDEXX anticipates a decline in U.S. same-store clinical visit growth of about 2% for 2026, reflecting macroeconomic challenges.
• The company noted a moderation in pricing growth expectations, with anticipated net price realization of approximately 4%, slightly lower than in 2025.

5. Notable Q&A Insights:

• Management acknowledged the divergence between wellness and non-wellness visits, attributing some of the decline in wellness visits to economic pressures on lower-income households.
• There is cautious optimism regarding the aging pet population potentially driving increased non-wellness visits in the future.
• Questions regarding consumables growth highlighted the importance of the installed base of premium instruments and innovations in driving utilization.
• The management indicated that while InVue placements are not yet fully penetrating corporate practices, they are seeing positive momentum and expect to increase placements in this segment.
• Discussions on pricing power revealed that while there has been some moderation, corporate practices are recognizing the need to balance pricing with demand to attract more clients.

Overall, IDEXX demonstrated strong financial performance in Q4 2025, driven by innovation and strategic growth initiatives, but faces challenges related to clinical visit trends and pricing dynamics as it moves into 2026.